A family office was considering an investment in a US-based biotech company developing a product aimed at improving impaired oxygen transport in COVID-19 patients. Using its expert network, Alacrita was commissioned to provide an opinion on the attractiveness of the investment, particularly focused on the scientific rational, strength of the clinical data and likelihood of approval.
Our clinical and scientific experts reviewed all preclinical and clinical documentation to evaluate the technical strength of the product. We also evaluated the competitive landscape and market opportunity to gain a commercial perspective. Key risks were identified which included several significant issues some of which were effectively showstoppers, and together with proposed mitigation strategies our findings were presented to the investor and the target company.
Due Diligence Services
Alacrita's due diligence experts have conducted over 200 major assignments for large pharma, biotech, universities and investors, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise expertise required for a complete, thorough and accurate assessment.Back